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Abstract
Sulforaphane (SFN), an isothiocyanate derived from cruciferous vegetables, induces potent anti-proliferative effects
in prostate cancer cells. One mechanism that may contribute to the anti-proliferative effects of SFN is the
modulation of epigenetic marks, such as inhibition of histone deacetylase (HDAC) enzymes. However, the effects of
SFN on other common epigenetic marks such as DNA methylation are understudied. Promoter hyper-methylation
of cyclin D2, a major regulator of cell cycle, is correlated with prostate cancer progression, and restoration of cyclin
D2 expression exerts anti-proliferative effects on LnCap prostate cancer cells. Our study aimed to investigate the
effects of SFN on DNA methylation status of cyclin D2 promoter, and how alteration in promoter methylation
impacts cyclin D2 gene expression in LnCap cells. We found that SFN significantly decreased the expression of DNA
methyltransferases (DNMTs), especially DNMT1 and DNMT3b. Furthermore, SFN significantly decreased methylation
in cyclin D2 promoter regions containing c-Myc and multiple Sp1 binding sites. Reduced methlyation of cyclin D2
promoter corresponded to an increase in cyclin D2 transcript levels, suggesting that SFN may de-repress
methylation-silenced cyclin D2 by impacting epigenetic pathways. Our results demonstrated the ability of SFN to
epigenetically modulate cyclin D2 expression, and provide novel insights into the mechanisms by which SFN may
regulate gene expression as a prostate cancer chemopreventive agent.
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Introduction
Studies have shown that high consumption of crucifer-
ous vegetables is inversely associated with prostate can-
cer risk [1-5]. Cruciferous vegetables and their
biologically active constituents, including isothiocyanates
(ITCs) such as sulforaphane (SFN), appear to modulate
prostate cancer risk at multiple stages of carcinogenesis.
SFN is an effective chemoprotective agent for prostate
cancer in both in vitro and in vivo models by selectively
inducing apoptosis and slowing tumor growth [6-10].
More recently, SFN has been shown to induce anti-pro-
liferative effects via epigenetics, namely acting as a diet-
ary histone deacetylase (HDAC) inhibitor. SFN
treatment leads to an increase in histone acetylation and
re-expression of various tumor suppressor genes
[11-13]. SFN-mediated epigenetic alterations may not
only be limited to HDAC regulation. Studies suggest
that SFN may play an important role in methyl CpG-
binding proteins’ recruitment of HDAC family members
[14]. In breast cancer cells, SFN suppresses DNA methy-
lation in the hTERT promoter, leading to transcriptional
repression [15]. Together, these data suggest that there
may be multiple mechanisms by which SFN epigeneti-
cally regulates gene expressions.
Cell cycle progression is controlled by cyclin-depen-
dent kinases (CDKs) and their activities are further
regulated by cyclins and CDK inhibitors. D-type cyclins
(D1, D2, and D3) are mainly implicated in G1 to S
phase transition [16]. Dys-regulation of the cyclin Ds
disrupts cell cycle control and promotes neoplastic
transformation. Cyclin D2/CCND2 has been identified
in several cancers as a proto-oncogene. Over-expression
of cyclin D2 correlates with progression and poor prog-
nosis in gastric cancer [17,18], colon cancer [19] and
granulosa cell tumors of the ovary [20]. However, silen-
cing of cyclin D2 expression by promoter methylation is
also associated with cancer progression in breast cancer
[21-23], lung [23], pancreatic [24] and gastric cancer
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any medium, provided the original work is properly cited.[25], suggesting that cyclin D2 might act as a tumor
suppressor gene in a cancer-type dependent manner. In
prostate cancer, increased cyclin D2 promoter methyla-
tion corresponds to a decrease in cyclin D2 mRNA
expression, and correlates with higher Gleason scores
and pathologic features of tumor aggressiveness [26].
The present study was undertaken to evaluate the effects
of SFN on the epigenetic regulation of cyclin D2 in
prostate cancer cells. Our results indicate that SFN may
down-regulate DNA methyltransferases (DNMTs)
resulting in de-methylation of the cyclin D2 promoter
and de-repression of cyclin D2 expression, and suggest a
novel mechanism behind SFN’s growth inhibitory effects
on prostate cancer cells.
Materials and methods
Cell Culture and Treatment
Benign prostate hyperplasia (BPH-1) cells were gener-
ously donated by Dr. Simon Hayward (Vanderbilt Uni-
versity Medical Center, Nashville, TN); androgen
dependent prostate cancer epithelial cells (LnCap) and
androgen-independent prostate cancer epithelial cells
(PC3) were obtained from America Type Culture Col-
lection (Manassas, VA). Cells were grown and main-
tained in RPMI 1640 supplemented with glutamine
(Mediatech Inc., Manassas, VA), 1% penicillin-strepto-
mycin (Mediatech Inc., Manassas, VA) and 10% (5% for
BPH-1 cells) fetal bovine serum (FBS) (Hyclone, Logan,
UT) under standard conditions (5% CO2 , 37°C, humidi-
fied atmosphere). R, S-Sulforaphane (SFN, LKT Labora-
tories, Inc., St. Paul, MN) was dissolved in dimethyl
sulfoxide (DMSO) or ethanol (EtOH) (Sigma-Aldrich).
Vehicle treatments consisted of DMSO or EtOH in a
final concentration matching the highest level of treated
cells (30 μMS F N )a n dw a sl e s st h a n0 . 1 %o ft h ef i n a l
volume. Cells were treated with vehicle or SFN (15 or
30 μM) for 24 or 48 hours.
mRNA expression levels of DNMTs by quantitative real-
time PCR (qRT-PCR)
Total RNA was extracted using TRIzol Reagent (Invitro-
gen, Carlsbad, CA) according to the manufacturer’s
instructions. Total RNA (1 μg) was reverse-transcribed
into cDNA using SuperScript III First-Strand Synthesis
Supermix (Invitrogen, Carlsbad, CA) containing reaction
buffer, MgCl2, dNTPs and a 1:1 mixture of random hex-
amers and oligo-dT primers. For qRT-PCR, the primer
sequences were as follows: DNMT1,( s e n s e )5 ’GTG
GGGGACTGTGTCTCTGT-3’ and (antisense) 5’-
TGAAAGCTGCATGTCCTCAC-3’; DNMT3a,( s e n s e )
5’-CACACAGAAGCATATCCAGGAGTG-3’ and (anti-
sense) 5’-AGTGGACTGGGAAACCAAATACCC-3’;
DNMT3b,( s e n s e )5 ’-AATGTGAATCCAGCCAG-
GAAAGGC-3’ and (antisense) 5’-ACTGGATTAC
ACTCCAGGAACCGT-3’; CCND2,( s e n s e )5 ’-
TGGAGCTGCTGTGCCACG -3’ and (antisense) 5’-
GTGGCCACCATTCTGCGC-3’ and GAPDH (sense) 5’-
CGAGATCCCTCCAAAATCAA- 3’ and (antisense) 5’-
TTCACACCCATGACGAACAT-3’.T h er e a c t i o n sw e r e
performed using DyNAmo HS SYBRGreen qPCR kit
(New England Biolabs, Ipswich, MA) on a Chromo4
Thermal Cycler (MJ Research, Inc., Waltham, MA). PCR
conditions were programmed as follows: 95°C for 5 min,
followed by 40 cycles of denaturing at 95°C for 10 s,
annealing at 60°C (62°C for CCND2) for 20 s, and exten-
sion at 72°C for 20 s. A dilution series of 10
2,1 0
3,1 0
4,1 0
5,
and 10
6 copies of template DNA served as internal stan-
dard for quantification. Gene copy numbers were calcu-
lated based on standard curves using Opticon Monitor 2
Software (MJ Research, Inc.) and normalized to GAPDH.
Data represent normalized fold-change +/- SEM.
Western blot analysis
Whole cell lysates were isolated by lysing cells with
immunoprecipitation (IP) buffer (25 mM HEPES, pH 7.4;
150 mM NaCl; 1 mM EDTA; 0.5% Triton X-100) fol-
lowed by flash freeze/thaw treatment and centrifugation.
Protein concentrations were determined by the Bradford
assay (Bio-Rad Protein Assay, Bio-Rad, Hercules, CA).
Proteins (20-30 μg) were separated by SDS-PAGE on a 4-
12% bis-Tris gel (NuPAGE Novex, Invitrogen, Carlsbad,
CA) and transferred to nitrocellulose membranes (Invi-
trogen). Ponceau S red staining and b-actin protein levels
were used as protein loading controls. Membranes were
incubated in primary antibodies specific against DNMT1
(1:1000) (Santa Cruz Biotechnology, Inc., Santa Cruz,
CA) overnight at 4°C. Secondary antibodies were conju-
gated with horseradish peroxidase (HRP) (Santa Cruz),
and proteins were detected by Western Lightning Chemi-
luminescence Reagent Plus (PerkinElmer Life Sciences,
Boston, MA) and imaged by Alpha Innotech photodocu-
mentation system. Densitometry and quantifications
were performed using NIH Image J software.
Bisulfite modification
Genomic DNA from cells was extracted using the DNeasy
Blood and Tissue Kit (Qiagen, Valencia, CA). Genomic
DNA (0.5-1 μg) was treated with sodium bisulfite via the
EZ DNA Methylation-Gold Kit (Zymo Research, Irvine,
CA). Bisulfite treatments changed unmethylated cytosines
into uracils while leaving methylated cytosines unmodified.
Bisulfite-treated genomic DNA was used for further analy-
sis of methylation status of CpG sites via methyl-specific
PCR (MSP) and bisulfite DNA sequencing.
Methyl-specific PCR (MSP)
PCR amplification was performed on the bisulfite–trea-
ted DNA samples using primer sets targeting CpG-rich
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sequences were based on previous reports and primer
binding positions were numbered from the transcrip-
tional start site [25]: unmethylated reaction, 5’-
GTTATGTTATGTTTGTTGTATG -3’ (sense, -1372 to
-1350), and 5’- TAAAATCCACCAACACAATCA -3’
(antisense, -1150 to -1170) and methylated reaction, 5’-
GTTACGTTATGTTCGTTGTACG -3’ (sense, -1372 to
-1350), and 5’- TAAAATCGCCGCCAACACGATCG -3’
(antisense, -1150 to -1173). PCR was conducted using
MSP buffer containing 16.6 mM ammonium sulfate, 67
mM Tris (pH 8.8), 6.7 mM MgCl2,a n d1 0m Mb-mer-
captoethanol. Touchdown PCR condition was as follows:
95°C for 5 min, followed by 10 cycles of 95°C for 30 s,
62°C for 30 s, 72°C for 45 s, and 30 cycles of 95°C for
30 s, 55°C for 30 s, 72°C for 45 s, and a final extension
step of 5 min at 72°C. PCR products (223-bp) were ana-
lyzed on 3% low melt agarose gels and stained with ethi-
dium bromide.
Bisulfite DNA sequencing
For bisulfite DNA sequencing analysis, genomic DNA
was digested with AflIII restriction enzyme (New Eng-
land Biolabs) and precipitated in the presence of GenE-
lute LPA (Sigma-Aldrich, St. Louis, MO) prior to
sodium bisulfite treatment. PCR primers were designed
to amplify a CpG-rich region spanning from -1700 to
-1250 bp from the transcription start site, which con-
tains 24 CpG sites. Bisulfite primer sequences were: 5’-
AGCTATTGGCTATGCAAATAGAGGG-3’ (-1670 to
-1645, forward) and 5’- CCCTTTAATATATTT-
CACTCCAA-3’ (-1261 to -1284, reverse). PCR condi-
tions described in the preceding section were used for
amplification. Following PCR amplification, gel-purified
bands were cloned into the pCR2.1 vector using the
TOPO TA Cloning Kit (Invitrogen). Multiple clones
(minimum of ten) from each PCR product were sub-
mitted for DNA sequencing at the Center for Genome
Research & Biocomputing Core Laboratories (Oregon
State University, Corvallis, OR). Transcription Element
Search Software (TESS) accessed through the World
Wide Web was used to identify transcription factor
binding sites within the cyclin D2 promoter region.
Global Methylation Status
Global methylation status of LnCap after treatments was
assessed by using the MethylFlash™ Methylated DNA
Quantification Kit (Epigentek, Brooklyn, NY) according
to manufacturer’s protocols with 200 ng of genomic
DNA.
Statistics
Data from independent triplicate (n = 3) experiments
were collected and statistical significance between SFN-
treated and other treatments were determined by one-
way ANOVA and Tukey-Krammer Multiple Compari-
son test using GraphPad Prism V5.0 software (Graph-
Pad, San Diego, CA). A P value of < 0.05 was
considered statistically significant.
Results
Sulforaphane decreased DNA methyltransferase
expression
We assessed the effects of SFN on the expressions of
DNMTs (DNMT1, DNMT3a,a n dDNMT3b)i nb e n i g n
hyperplasia (BPH-1), LnCap and PC3 prostate cancer
cells. Cells were treated with SFN (15 μMa n d3 0μM),
and assayed for DNMT1, 3a and 3b transcript levels
after 48 h. DNMT1 protein expression was also exam-
ined by western blot in treated cells. In BPH-1 and PC3
cells, SFN at both treatment doses significantly
decreased DNMT1 and 3a mRNA expression, but did
not significantly change DNMT1 protein expression
(Figure 1). In LnCap cells, SFN significantly decreased
DNMT1 and 3b mRNA expressions, and DNMT1 pro-
tein expression (Figure 1). Previous study indicated that
concentrations around 10 μM SFN effectively inhibited
HDAC activity in colonic mucosa in vivo,a n do n e
would consume about 1 cup (106 g) of broccoli sprouts
per day to achieve similar plasma levels in humans [27].
This shows that the lowest treatment concentration in
this study (15 μM) that decreased DNMT expressions
was within practical limits. 5-Aza-dC did not signifi-
cantly affect DNMTs expression, indicating that 5-Aza-
dC inhibits DNMT enzymatic activity rather than
expression, consistent with the mechanism by which 5-
Aza-dC inhibits DNMT through direct binding [28].
Alternatively, global inhibition of DNA methylation by
5-Aza-dC treatments may result in AP-1 dependent
induction of DNMT1 expression similarly to observation
in mouse embryonal cell line, P19 [29]. SFN appeared to
most significantly suppress transcript and protein levels
of DNMTs in LnCap cells. Previous studies also demon-
strated that over-expression of cyclin D2 induced anti-
proliferative effects on LnCap cells, but not PC3 cells
[30]. Therefore, LnCap cells were used to study subse-
quent endpoints.
Sulforaphane decreased global DNA methylation and
Cyclin D2 promoter methylation
DNA methylation plays an important role in regulating
cyclin D2 expression ([20-23,25,26,31]. To explore the
effects of SFN on DNA methylation, we first examined
the effects of SFN treatment on the global methylation
status of LnCap cells, followed by detailed investigation
of the methylation status of cyclin D2 promoter region
via methyl-specific PCR (MSP) and bisulfite sequencing
analysis. SFN (30 μM) and 5-Aza-dC significantly
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treatments (Figure 2), suggesting systematic de-methy-
lating effects by SFN.
To specifically investigate the promoter methylation
status of cyclin D2, an initial screen for cyclin D2 pro-
moter methylation was performed by MSP, followed by
verification via bisulfite sequence analysis. MSP screen-
ing suggested that there was a trend of decreasing
methylation associated with increasing SFN treatment
(Figure 3). Treatment with de-methylating agent, 5-Aza-
dC, significantly increased un-methylated product com-
pared to control. Since MSP is limited to provide semi-
quantitative analysis of a few CpG sites; we verified the
MSP findings with bisulfite sequencing. To study the
extent of promoter methylation, the CpG-rich region of
the cyclin D2 promoter further upstream spanning
nucleotides -1700 to -1250 bp (a total of 24 CpG sites)
was sequenced after bisulfite modification of genomic
DNA from cells treated with SFN for 48 h. As shown in
Figure 4, the CpG island examined was partially
a b
Figure 1 SFN decreased mRNA and protein expressions of DNA methyltransferases in prostate cancer cells. a. Benign hyperplasia cells
(BPH-1), LnCap and PC3 cells were treated with SFN (15 and 30 μM) or 5-Aza-dC (5 μM) for 48 h. RNA was extracted and cDNA synthesized for
qRT-PCR. Values are fold change of gene copy numbers normalized to GAPDH and compared to vehicle. b. Whole cell lysates were extracted
and DNMT1 protein levels were analyzed by western blot. The lower graph represents the relative density of DNMT1 normalized to b-actin levels.
Results represent means ± SEM, n = 3. P values represent treatment values compared to vehicle.
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5-Aza-dC treatment produced a trend toward decreased
methylation, and SFN-treatment resulted in a significant
decrease in methylated CpG sites in this region. In par-
ticular, the c-Myc transcription factor binding site at
CpG residue 23 and 24 were hyper-methylated in
vehicle control, and SFN treatment significantly
decreased methylation at these CpG sites (p < 0.05).
Sulforaphane induced cyclin D2 expression in LnCap Cells
Previous reports stated that promoter methylation of
cyclin D2 was associated with transcriptional silencing
in gastric cancer cell lines [25]. By using qRT-PCR,
cyclin D2 mRNA expression was determined in prostate
cancer cells treated with SFN. At 24 h, SFN dose-depen-
dently increased cyclin D2 mRNA expression (Figure 5).
There were no significant changes in cyclin D2 mRNA
levels associated with 5-Aza-dC treatment (data not
shown), possibly due to shorter treatment time com-
pared to previous reports. Previous studies showed that
the ability of 5-Aza-dC to enhance expression of cyclin
D2 was more marked if gastric cancer cells were treated
for at least 5 days [25].
Discussion
Epigenetic silencing through promoter hypermethylation
and histone deacetylation is responsible for transcrip-
tional repression of numerous tumor suppressor genes
and growth regulatory genes in cancer cells [32-34]. A
tightly regulated balance exists in normal cells among
these processes, but disruption of this balance contri-
butes to carcinogenesis. Recent studies have suggested
novel chemo-preventative properties of SFN as an
HDAC and DNMT inhibitor [15,35]. SFN was shown to
have anti-proliferative and pro-apoptotic effects in many
cancer cells, including prostate cancer [35-37]. However,
the molecular mechanisms by which SFN regulates var-
ious genes that govern these processes remain to be elu-
cidated. The current study demonstrates that SFN also
impacts global DNA methylation and site-specific de-
methylation of the cyclin D2 promoter. These results
suggest that the ability of SFN to alter DNA methylation
of specific tumor suppressor genes may be an important
mechanism leading to prostate chemoprevention.
Previous studies indicate that cyclin D2 promoter
methylation is more extensive in malignant than non-
malignant human prostate tissue [31] and treatment
with 5-Aza-dC and TSA increased cyclin D2 expression
in prostate cancer cell lines [30]. In the same study,
over-expression of cyclin D2 induced anti-proliferative
effects on LnCap cells, but not PC3 cells, suggesting
that the inhibitory effects of cyclin D2 is limited to AR-
dependent prostate cancer cells [30]. Similar to previous
reports, our study showed that LnCap cells had lower
expression of cyclin D2 compared to BPH-1 cells, a
non- tumorigenic cell line (data not shown). Previous
studies have implicated that SFN is an HDAC inhibitor.
In prostate cancer cells, such as LnCap and PC3 cells,
SFN treatment significantly inhibits HDAC activity
[35,38]. Combined with findings from these studies,
Figure 2 Sulforaphane decreased global DNA methylation.
LnCap cells were treated with SFN (15 and 30 μM) or 5-Aza-dC (5
μM) for 24 h. Genomic DNA was extracted and treated with sodium
bisulfite. Global methylation status was fluorometrically quantified in
a microplate-based ELISA assay. Values were derived as fold change
compared to vehicle (DMSO) and represent means ± SEM, n = 3. P
values represent treatment values compared to vehicle.
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Figure 3 Sulforaphane decreased promoter methylation of
cyclin D2. Methylation-specific PCR was performed after bisulfite
modification of DNA from LnCap cells treated for 48 h. Upper
figures are representative bands. UM indicates unmethylated cyclin
D2 PCR products. M indicates methylated PCR products. The lower
figure shows the levels of unmethylated versus methylated cyclin D2
PCR products by densitometry based on biological triplicates. SFN
and 5-Aza-dC both decreased cyclin D2 promoter methylation. P
values represent treatment values compared to vehicle.
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in part, through de-methylation of the cyclin D2 promo-
ter and restoration of cyclin D2 expression. It is possible
that SFN-mediated both HDAC and DNMT inhibition
and collectively allows chromatin remodeling for access
of various transcription factors and de-suppression of
the cyclin D2 promoter.
To identify potential DNA methylation changes
mediated by SFN, we examined the global methylation
status and the methylation status of CpG islands in the
cyclin D2 promoter region (-1700 to -1250) in LnCap
cells. The methylation analysis indicated that 5-Aza-dC
induced more systemic de-methylation by significantly
decreasing global methylation, whereas SFN showed
more pronounced de-methylating effects in the cyclin
D2 promoter region. More specifically, there was a sig-
nificant decrease in methylation at the transcription fac-
tor c-Myc binding region. C-Myc has been implicated in
modulating gene expression through epigenetic modifi-
cations. Classically, c-Myc’s repressive effects on gene
expression are attributed to inhibition of Sp1 transcrip-
tional activity [39], and cyclin D2 is directly induced by
c-Myc [40]. More recently, it was suggested that c-Myc
modulates DNMT activity through direct binding or
indirectly through an interaction with Mitz-1 to repress
transcriptional activity, such as observed with the p21
Vehicle
30PMSFN
5ͲAzaͲdC
Ͳ1700 Ͳ1250bp
cMyc
E2F
35%methylation
30%methylation(p<0.05)
75%methylation
CpG# 1    2    3   4   5    6   7   8   9  10 11  12 13 14 15 16 17  18 19  20 21 22  23 24 
Transcription
startsite
Ͳ1600Ͳ1400Ͳ1200Ͳ1000bp
BiͲsulfitesequencing
MSP
Figure 4 Bisulfite sequencing of cyclin D2 promoter region. The nucleotide sequence -1700 to -1250 bp from the transcription start site of
the cyclin D2 gene promoter for the bisulfite sequencing analysis, and the relative regions of amplifications by MSP and bisulfite sequencing are
shown. Genomic DNA from LnCap cells treated for 48 h was sodium bisulfite-treated, PCR amplified and subcloned. The sequencing results from
15-20 clones were used for analysis (upper figure, p values represent treatment values compared to vehicle), and representative 10 clones are
shown in the dot plot. Each horizontal line represents the sequencing result of one subclone. Methylated CpG sites are shown as solid circles,
whereas open circles indicate unmethylated CpG sites.
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sequence of c-Myc DNA binding site (CACGTG) con-
tains a CpG site which is frequently methylated in vivo.
Methylation of the consensus site blocks Myc/Max
binding and trans-activation, but whether this influences
the dynamics of Myc/Max heterodimer interactions with
chromosomes remains to be elucidated [43]. It is impor-
tant to recognize that global de-methylation has also
been linked to increase genomic instability, and future
studies are crucial to investigate whether such effects
are advantageous for chemo-prevention using de-methy-
lating compounds such as SFN. Furthermore, it is
unclear how SFN treatment leads to selective de-methy-
lation of specific CpG sites, but SFN may indirectly
affect regulations of DNMTs and their specificities
toward certain CpG sites. Nevertheless, SFN’s effect on
de-methylating the c-Myc binding site suggests that
restoration of transcriptional expression of cyclin D2
may be dependent on c-Myc trans-activation. Future
experiments utilizing chromatin immunoprecipitation
(ChIP) will be essential to elucidate the detailed interac-
tions and the role of c-Myc binding. Furthermore, it is
possible that other regions may demonstrate more pro-
nounced differential methylation pattern with SFN treat-
ment. The analysis of other regions on the promoter
and their impact on cyclin D2 re-expression is an
important area for future research. Moreover, the higher
treatment concentration (30 μM) in this study that
altered methylation pattern in the cyclin D2 promoter
(Figure 4) was a somewhat high concentration compared
to SFN derived from dietary sources. However, it is pos-
sible that longer exposure of SFN at lower dosages
could achieve the same outcomes. The findings here
p r o v i d eap r o o fo fc o n c e p to ft h ee f f e c t so fS F No n
DNA methylation, but the precise dosing regimens and
treatment timing to obtain optimal effects are important
areas of research.
Consistent with previous findings that SFN decreased
expression of DNMT1 and DNMT3a in breast cancer
cells [15], SFN also decreased DNMTs expressions in
our study. We found that DNMT1 and 3a mRNA
expressions were significantly decreased by SFN in
BPH-1 and PC3 cells, but only a trend of decrease in
DNMT1 protein expression. In contrast, we found that
DNMT1 and 3b were down-regulated with SFN treat-
ment in LnCap cells, but not DNMT3a.T h e s er e s u l t s
suggest that the responses to SFN treatment are specific
to cell types. SFN may act as a dual epigenetic regulator
by inhibiting both HDACs and DNMTs, leading to
altered gene expression and contribute to anti-prolifera-
tive effects. It has been well established that DNA
methylation and histone modifications cross-talk and
cooperate in the regulation of gene transcription. Recent
in vitro studies have shown that DNMT1 interacts phy-
sically with HDAC1 or 2. DNMTs recruit class 1
HDACs to function as co-repressors in the transcription
of tumor suppressor genes [44-46]. Jones et al. demon-
strated that trichostatin A (TSA), a HDAC inhibitor,
relieves transcriptional repression at methylated CpG
islands, and implicated that DNA methylation provided
the nucleosomal infrastructure for HDAC-dependent
chromatin modification and transcriptional silencing
[34,47]. The SFN-mediated inhibition of DNMT expres-
sions may be an important contributing factor in facili-
tating de-methylation of cyclin D2 promoter observed in
this study. In addition to transcriptional regulation of
DNMTs, it is also possible that alternative post-tran-
scriptional and post-translational regulations of DNMTs
a r et a r g e t e db yS F N .S F Nm a ym o d u l a t eh i s t o n ep r o f i l e
and DNMT pathways at the same time. Previous studies
from our lab established that SFN (≥ 15 μM) signifi-
cantly decreased HDAC activity and expressions in
LnCap cells [38,48]. SFN also potently increased p21
expressions. DNMT1 has been shown to competitively
bind to proliferating nuclear cell antigen (PCNA) at the
same site as p21, a tumor suppressor that inhibits DNA
replication [49]. In ovarian cancer cells, SFN inhibits
degradation of retinoblastoma protein (Rb), which
directly binds to DNMT1, sequesters its activity and dis-
rupts formation of DNMT-DNA complexes [46,50]. It is
very likely that SFN regulates DNMT indirectly through
HDACs or other protein interactions. Further examina-
tion of the direct coordination between these epigenetic
marks is an exciting area for future studies. Studies that
identify specific methyl binding proteins, transcriptional
activators or repressors and chromatin remodeling will
be essential to decipher the exact mechanism of cyclin
Figure 5 Sulforaphane increased transcript levels of cyclin D2.
LnCap cells were treated with SFN (15 and 30 μM) for 24 h. RNA
was extracted and cDNA synthesized for qRT-PCR. SFN increased
transcript levels of cyclin D2 compared with vehicle (DMSO). Values
are fold change of gene copy numbers normalized to GAPDH and
compared to vehicle, and represent means ± SEM, n = 3. P values
represent treatment values compared to vehicle.
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decreased telomerase reverse transcriptase (hTERT)
expression through promoter de-methylation and epige-
netic modulations in breast cancer cells, suggesting that
SFN may target other hypermethylated gene promoters
that are dys-regulated during carcinogenesis and warrant
further investigation. Overall, we demonstrated the SFN
induced up-regulation of cyclin D2 in prostate cancer
cells, and examined SFN as an epigenetic modulator by
altering methylation status in the cyclin D2 promoter
region. These findings provide additional insights into
the mechanisms by which SFN may act as a diet-derived
epigenetic modulator of gene expression and agent for
prostate cancer prevention.
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